Search
for
Sort by
Research 151–180 of 1000+
- Effect of 5-alpha reductase inhibitors in animal models of Parkinson’s disease
- Risk of Estrogen-Driven Malignancies in Females on 5-alpha Reductase Inhibitors
- Recent trends in nanocarrier formulations of actives beyond minoxidil and 5-α reductase inhibitors in androgenetic alopecia management: A systematic review
- Effects of Solvent System and Storage Condition on Chemical Stability of 5(alpha)-Reductase Inhibitor Compounds in Tectona grandis L.f. Leaf Extracts
- pH STIMULUS-RESPONSIVE HYBRID NANOPARTICLES: A SYSTEM DESIGNED FOR FOLLICULAR DELIVERY OF BRAZILIAN PLANT-DERIVED 5-ALPHA-REDUCTASE ENZYME INHIBITORS
- Evaluating 5 alpha reductase inhibitors for the treatment of male androgenic alopecia
- Litigation associated with 5-alpha-reductase-inhibitor use: A Canadian legal database review.
- 5-alpha reductase inhibitors use in prostatic disease and beyond
- Adverse Effects of 5-Alpha-Reductase Inhibitors: a narrative review
- Isolation and HPLC Quantitative Determination of 5α-Reductase Inhibitors from Tectona grandis L.f. Leaf Extract
- MP44-04 TRENDS IN 5-ALPHA REDUCTASE INHIBITOR USE BEFORE AND AFTER THE FOOD AND DRUG ADMINISTRATION SAFETY WARNING
- Alpha Blocker and 5-Alpha Reductase Inhibitor Prescribing Habits among Urologists and Primary Care Physicians
- 1153 ERECTILE HEMODYNAMICS ASSESSMENT IN MEN WITH PERSISTENT ERECTILE DYSFUNCTION AFTER 5-ALPHA REDUCTASE INHIBITOR USE
- Patent Evaluation: Δ-4,6-Steroids as Potent 5α-Reductase Inhibitors
- Absence of Interaction Between 5α‐Reductase Inhibitors and Glucocorticoids on Incidence of Myocardial Infarction in People With Type 2 Diabetes
- (719) Signal Detection of Depression and Suicidality With the 5-Alpha Reductase Inhibitors: Evidence from the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) Database
- Impact of 5-alpha Reductase Inhibitors on Male Reproductive Health: A Review of Finasteride and Dutasteride.
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study
- Supplementary Material for: Drug-Induced Melasma in Patients on 5-Alpha Reductase Inhibitors: A Case Report
- Supplementary Material for: Drug-Induced Melasma in Patients on 5-Alpha Reductase Inhibitors: A Case Report
- Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study
- Depression risk of 5-alpha reductase inhibitors: A systematic review and meta-analysis with a focus on comparator groups
- An exploratory analysis of 5‐alpha reductase inhibitors and risk of opioid use disorder among male Medicare beneficiaries receiving prescription opioid medications
- Comparative Efficacy of Minoxidil and 5‐Alpha Reductase Inhibitors Monotherapy for Male Pattern Hair Loss: Network Meta‐Analysis Study of Current Empirical Evidence
- 5-Alpha Reductase Inhibitors on Hypersexuality During the Manic Phase of Bipolar and Psychotic Patients; New Insight to a Well-Known Medicines
- Risk associated with the use of 5-alpha reductase inhibitors with minoxidil in treatment of male androgenetic alopecia – literature review
- 5-Alpha-Reductase Inhibitors in the Treatment of Male Androgenetic Alopecia: Clinical Experience
- LB891 Analysis of breast health outcomes in women on oral 5-alpha reductase inhibitors: A single-center retrospective cohort study